Cardiovascular outcomes in type 2 diabetes: The impact of preventative therapies

Annals of the New York Academy of Sciences

Volumn 1212, Issue , 2010, Pages 29-40

  Zoungas, Sophia ^a,b   Patel, Anushka ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Cardiovascular disease; Preventive therapies; Type 2 diabetes

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE; PERINDOPRIL;

ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETIC PATIENT; DISABILITY; FOLLOW UP; HEART PROTECTION; HUMAN; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; PRIMARY PREVENTION; PROPHYLAXIS;

EID: 78649486408     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05837.x     Document Type: Article

References (30)

1. International Diabetes Federation, Diabetes Atlas 2009; 4th Ed.
2. Standards of medical care in diabetes-2009. Diabetes Care 2009;32(Suppl 1): S13-S61.
3. Adler, A.I., I.M. Stratton, H.A. Neil, et al 2000. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ (Clinical research (Ed) 321: 412-419.
4. Patel, A., S. MacMahon, J. Chalmers, et al 2008. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358: 2560-2572.
5. Patel, A., S. MacMahon, J. Chalmers, et al 2007. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370: 829-840.
6. Cushman, W.C., G.W. Evans, R.P. Byington, et al 2010. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N. Engl. J. Med. 362: 1575-1585.
7. Gerstein, H.C., M.E. Miller, R.P. Byington, et al 2008. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 358: 2545-2559.
8. Ginsberg, H.N., M.B. Elam, L.C. Lovato, et al 2010.Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. 362: 1563-1574.
9. UK Prospective Diabetes Study Group. 1998. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ (Clinical research (Ed) 317: 703-713.
10. Holman, R.R., S.K. Paul, M.A. Bethel, et al 2008. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N. Engl. J. Med. 359: 1565-1576.
11. Yusuf, S., H.C. Diener, R.L. Sacco, et al 2008.Telmisartan to prevent recurrent stroke and cardiovascular events. N. Engl. J. Med. 359: 1225-1237.
12. Jamerson, K., M.A. Weber, G.L. Bakris, et al 2008. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 359: 2417-2428.
13. The Diabetes Control and Complications Trial Research Group. 1995. Effects of intensive diabetes management on macrovascular disease and risk factors in the Diabetes Control and Complications Trial. Am. J. Cardiol. 75: 894-903.
14. The DCCT/EDIC Research Group. 2005. Intensive diabetes treatment and cardiovascular disease in patients with Type 1 diabetes. N. Engl. J. Med. 353: 3643-3453.
15. UK Prospective Diabetes Study (UKPDS) Group. 1998. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837-853.
16. UK Prospective Diabetes Study (UKPDS) Group. 1998. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854-865.
17. Duckworth, W., C. Abraira, T. Moritz, et al 2009. Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med. 360: 129-139.
18. Holman, R.R., S.K. Paul, M.A. Bethel, et al 2008. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 359: 1577-1589.
19. Turnbull, F.M., C. Abraira, R.J. Anderson, et al 2009. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 52: 2288-2298.
20. Baigent, C., A. Keech, P.M. Kearney, et al 2005. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 366: 1267-1278.
21. Keech, A., J. Simes, P. Barter, et al 2006. Correction to the FIELD study report. Lancet 368: 1415.
22. Keech, A., R.J. Simes, P. Barter, et al 2005. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366: 1849-1861.
23. Jun, M., C. Foote, J. Lv, et al. 2010. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 375: 1875-1884.
24. Antithrombotic Trialists' Collaboration. 2002. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ (Clinical research ed 2002) 324: 71-86.
25. Ogawa, H., M. Nakayama, T. Morimoto, et al 2008. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 300: 2134-2141.
26. Belch, J., A. MacCuish, I. Campbell, et al 2008. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 337:a1840.
27. Haynes, R., L. Bowman, J. Armitage 2009. Aspirin for primary prevention of vascular disease in people with diabetes. BMJ 339: b4596.
28. Zoungas, S., B.E. De Galan, T. Ninomiya, et al 2009. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial. Diabetes Care 32: 2068-2074.
29. Gaede, P., P. Vedel, N Larsen, et al 2003. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 348: 383-393.
30. Gaede, P., H. Lund-Andersen, H.H. Parving, O. Pedersen, 2008. Effect of a multifactorial intervention on mortality in type 2 diabetes. N. Engl. J. Med. 358: 580-591.